| Absorption | Well absorbed following subcutaneous administration, with a mean bioavailability of 92% (based on anti-factor Xa activity). |
| Volume of distribution | Not Available |
| Protein binding | Not Available |
| Metabolism | Liver and the reticulo-endothelial system are the sites of biotransformation. |
| Route of elimination | Not Available |
| Half life | Elimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose. |
| Clearance | Not Available |
| Toxicity | Symptoms of overdose may include excessive bleeding and bruising. |
| Affected organisms |
|
Ardeparin
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment